Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

698

Enrollment

INDUSTRY

Sponsor class

Conditions

Abscess
Wound Infection
Surgical Site Infection
Cellulitis

Interventions

DRUG: Dalbavancin
DRUG: Dalbavancin-matching Placebo

Sponsor

Durata Therapeutics Inc., an affiliate of Allergan plc